The partnership will enable the Applied Process Company (APC) and the National Institute for Bioprocessing Research & Training (NIBRT) to provide increased access to R&D and analytical services.
The Applied Process Company (APC) and the National Institute for Bioprocessing Research & Training (NIBRT) announced on April 2, 2019 that the companies signed a strategic partnership agreement to provide their respective client bases with increased access to R&D and analytical services across their complementary biopharmaceutical services.
According to NIBRT, the partnership is expected to better serve the complex needs of the shared client base by leveraging APC’s process development and optimization services through application of its process analytical technology, combined with NIBRT’s extensive biopharmaceutical services and knowledge in single-use, pilot plant, and bioanalytical capabilities.
APC reports that it has been using NIBRT’s expertise to complement its own analytical development services in certain areas for several years. This agreement expands the companies’ partnership to offer their combined client base access to the broader complementary services.
“We welcome this logical extension to our current relationship with NIBRT and recognize the value of their biopharmaceutical services, complementing our own in-house bioprocess development and optimization technologies, which have recently benefited from multimillion-euro investment,” said APC Chief Commercial Officer David Downey, in a press release. “This mutually beneficial arrangement will further increase our capabilities in delivering complex process development solutions to our global client base.”
“Our global client base has complex bioanalytical characterization and process development requirements to support their development of their innovative therapeutics,” said Killian O’Driscoll, director of projects at NIBRT, in the release. “We’re delighted to announce the further strengthening of our partnership with APC to assist clients design, develop, and characterize their biological processes and products.”
Source: NIBRT
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.